Bio-Rad Laboratories, Inc. (BIO.B) stock
BIO.BNYSELaboratory Analytical InstrumentsFiscal year ends December 31Also trades as BIO
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 8/3055% above fair value
$379.50+0.00 (0.00%)
Close on Oct 29, 2026Market cap $10.18BP/E 46.2Yield –
Bio-Rad Laboratories revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Bio-Rad Laboratories's revenue for the twelve months ending Jun 30, 2026 was $2.59B, up 1.4% year over year. For fiscal 2025 it was $2.58B, up 0.7% from the year before. Over ten years it grew 2.5% a year on average. The highest annual figure on record is $2.92B in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.58B | +0.7% |
| FY2024 | Dec 31, 2024 | $2.57B | -3.9% |
| FY2023 | Dec 31, 2023 | $2.67B | -4.7% |
| FY2022 | Dec 31, 2022 | $2.80B | -4.1% |
| FY2021 | Dec 31, 2021 | $2.92B | +14.8% |
| FY2020 | Dec 31, 2020 | $2.55B | +10.1% |
| FY2019 | Dec 31, 2019 | $2.31B | +1.0% |
| FY2018 | Dec 31, 2018 | $2.29B | +6.0% |
| FY2017 | Dec 31, 2017 | $2.16B | +4.4% |
| FY2016 | Dec 31, 2016 | $2.07B | +2.4% |
| FY2015 | Dec 31, 2015 | $2.02B | -7.2% |
| FY2014 | Dec 31, 2014 | $2.18B | +2.0% |
| FY2013 | Dec 31, 2013 | $2.13B | +3.1% |
| FY2012 | Dec 31, 2012 | $2.07B | -0.2% |
| FY2011 | Dec 31, 2011 | $2.07B | +7.6% |
| FY2010 | Dec 31, 2010 | $1.93B | +8.0% |
| FY2009 | Dec 31, 2009 | $1.78B | +1.1% |
| FY2008 | Dec 31, 2008 | $1.76B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $651.00M | -0.1% |
| Q1 FY2026 | Mar 31, 2026 | $592.10M | +1.1% |
| Q4 FY2025 | Dec 31, 2025 | $693.20M | +3.9% |
| Q3 FY2025 | Sep 30, 2025 | $653.00M | +0.5% |
| Q2 FY2025 | Jun 30, 2025 | $651.60M | +2.1% |
| Q1 FY2025 | Mar 31, 2025 | $585.40M | -4.2% |
| Q4 FY2024 | Dec 31, 2024 | $667.50M | -2.0% |
| Q3 FY2024 | Sep 30, 2024 | $649.70M | +2.8% |
| Q2 FY2024 | Jun 30, 2024 | $638.50M | -6.3% |
| Q1 FY2024 | Mar 31, 2024 | $610.80M | -9.8% |
| Q4 FY2023 | Dec 31, 2023 | $681.20M | -6.7% |
| Q3 FY2023 | Sep 30, 2023 | $632.10M | -7.2% |
| Q2 FY2023 | Jun 30, 2023 | $681.10M | -1.4% |
| Q1 FY2023 | Mar 31, 2023 | $676.80M | -3.3% |
| Q4 FY2022 | Dec 31, 2022 | $730.30M | -0.3% |
| Q3 FY2022 | Sep 30, 2022 | $680.80M | -8.9% |
| Q2 FY2022 | Jun 30, 2022 | $691.10M | -3.5% |
| Q1 FY2022 | Mar 31, 2022 | $700.10M | -3.7% |
| Q4 FY2021 | Dec 31, 2021 | $732.80M | -7.2% |
| Q3 FY2021 | Sep 30, 2021 | $747.00M | +15.4% |
| Q2 FY2021 | Jun 30, 2021 | $715.90M | +33.3% |
| Q1 FY2021 | Mar 31, 2021 | $726.80M | +27.2% |
| Q4 FY2020 | Dec 31, 2020 | $789.80M | +26.5% |
| Q3 FY2020 | Sep 30, 2020 | $647.30M | +15.5% |
| Q2 FY2020 | Jun 30, 2020 | $536.90M | -6.2% |
| Q1 FY2020 | Mar 31, 2020 | $571.60M | +3.2% |
| Q4 FY2019 | Dec 31, 2019 | $624.50M | +1.2% |
| Q3 FY2019 | Sep 30, 2019 | $560.60M | +2.8% |
| Q2 FY2019 | Jun 30, 2019 | $572.60M | -0.6% |
| Q1 FY2019 | Mar 31, 2019 | $554.00M | +0.5% |
| Q4 FY2018 | Dec 31, 2018 | $616.90M | -0.7% |
| Q3 FY2018 | Sep 30, 2018 | $545.10M | +2.1% |
| Q2 FY2018 | Jun 30, 2018 | $575.90M | +14.1% |
| Q1 FY2018 | Mar 31, 2018 | $551.50M | +10.3% |
| Q4 FY2017 | Dec 31, 2017 | $621.30M | +8.7% |
| Q3 FY2017 | Sep 30, 2017 | $534.10M | +5.0% |
| Q2 FY2017 | Jun 30, 2017 | $504.70M | – |
| Q1 FY2017 | Mar 31, 2017 | $500.10M | – |
| Q4 FY2016 | Dec 31, 2016 | $571.50M | – |
| Q3 FY2016 | Sep 30, 2016 | $508.70M | – |